C11470: Biomarkers for Aggressive Prostate CancerNovelty:
This technology comprises the discovery of novel biomarkers which could be useful for cancer diagnosis and monitoring the treatment of aggressive prostate tumor.
Value Proposition:
Existing technologies fail to reliably distinguish aggressive prostate cancer from non-aggressive prostate cancer. The disclosed technology serves as efficient biomarker, potentially useful as a diagnostic tool to differentiate patients with aggressive prostate cancer from those with non aggressive cancer. The advantages include:
• Identification of four glycoproteins specific to aggressive prostate cancer.
• Potentially useful for diagnosis and monitoring the treatment of aggressive prostate tumor.
• Biomarkers prevent patients with nonaggressive prostate cancer from overtreatment and allow patients with aggressive cancer to receive appropriate treatment earlier in the course of their disease.
Technical Details:
Johns Hopkins researchers have identified protein biomarkers related to aggressive prostate cancer and further verified the protein candidates using antibody based methods. The glycoproteins were quantified from prostate tissues using quantitative proteomic analysis. Specifically, the researchers identified proteins associated with aggressive prostate cancer using OCT-embedded frozen tissues with patient follow up and known clinical outcome. Tumor tissues were cryostat microdissected from 4 cases of aggressive and 4 cases of nonaggressive prostate tumors, and glycopeptides were isolated and labeled with iTRAQ reagents before the samples were analyzed with LTQ Orbitrap Velos mass spectrometer.
Looking for Partners:
To develop & commercialize the technology as an efficient diagnostic assay tool for prostate cancer diagnosis/prognosis.
Stage of Development:
Pre-Clinical
Data Availability:
Under CDA / NDA
Publications/Associated Cases:
Cancer. Anal. Chem., 2011, 83 (18), 7013–7019
